Ambrx Biopharma (Ambrx Biopharma) Days Payable : 0.00 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Ambrx Biopharma Days Payable?

Ambrx Biopharma's average Accounts Payable for the three months ended in Jun. 2023 was $4.78 Mil. Ambrx Biopharma's Cost of Goods Sold for the three months ended in Jun. 2023 was $0.00 Mil.

The historical rank and industry rank for Ambrx Biopharma's Days Payable or its related term are showing as below:

AMAM's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 149.7
* Ranked among companies with meaningful Days Payable only.

Ambrx Biopharma's Days Payable stayed the same from Jun. 2021 (0.00) to Jun. 2023 (0.00). stayed the same

Ambrx Biopharma Days Payable Historical Data

The historical data trend for Ambrx Biopharma's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ambrx Biopharma Days Payable Chart

Ambrx Biopharma Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Days Payable

Ambrx Biopharma Quarterly Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Days Payable	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Ambrx Biopharma's Days Payable

For the Biotechnology subindustry, Ambrx Biopharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ambrx Biopharma's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ambrx Biopharma's Days Payable distribution charts can be found below:

* The bar in red indicates where Ambrx Biopharma's Days Payable falls into.

Ambrx Biopharma Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Ambrx Biopharma's Days Payable for the fiscal year that ended in Dec. 2022 is calculated as

	Days Payable (A: Dec. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2021 )	+	Accounts Payable (A: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2022 )	*	Days in Period
=	( (5.272	+	3.205)	/	2 )	/	0	*	365
=	4.2385					/	0	*	365
=	N/A

Ambrx Biopharma's Days Payable for the quarter that ended in Jun. 2023 is calculated as:

	Days Payable (Q: Jun. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2022 )	+	Accounts Payable (Q: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2023 )	*	Days in Period
=	( (3.205	+	6.362)	/	2 )	/	0	*	365 / 4
=	4.7835					/	0	*	365 / 4
=	N/A

Ambrx Biopharma Days Payable Related Terms

Thank you for viewing the detailed overview of Ambrx Biopharma's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Ambrx Biopharma (Ambrx Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ambrx Biopharma Inc (NAS:AMAM) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

AMAM:USA

Address

10975 North Torrey Pines Road, La Jolla, CA, USA, 92037

Website

https://www.ambrx.com

Ambrx Biopharma Inc is a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform that allows incorporating synthetic amino acids (SAAs) into proteins within living cells. Its product pipeline includes ARX788, ARX517, ARX305 among others.

Executives

Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Margaret Dalesandro	director	ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Sonja Nelson	officer: Chief Financial Officer	C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BOULEVARD, 3RD FLOOR, FT. LAUDERDALE FL 33301
Daniel J. O'connor	director, officer: President and CEO	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Abhishek Trehan	10 percent owner	WHITELEY CHAMBERS, DON STREET, ST. HELIER Y9 JE2 4TR
Darwin Global Master Fund, Ltd.	10 percent owner	C/O OGIER GLOBAL (CAYMAN) LIMITED, 89 NEXUS WAY, CAMANA BAY, GRAND CAYMAN E9 KY1-9009
Paul V Maier	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Janet Loesberg	director	C/O AMBRX BIOPHARMA INC., 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Kate Hermans	director	C/O AMBRX BIOPHARMA INC., 10975 TORREY PINES ROAD, LA JOLLA CA 92037
Xiaowei Chang	director	10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Stephen C. Glover	director	108 DOCKSIDE CIRCLE, WESTON FL 33327
Andrew Aromando	officer: Chief Operating Officer	C/O AMBRX BIOPHARMA INC., 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Cormorant Private Healthcare Fund Iii Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen	10 percent owner	C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116